24 Oct 2018 I The release and presentation materials are now available.
The 2019 Annual General Meeting is planned to be held on 26 March 2019 in Helsinki.
The results of the ARAMIS phase III trial of darolutamide in non-metastatic castration-resistant prostate cancer will be presented on 14 February 2019 at the Genitourinary Cancers Symposium (ASCO GU).
The Closing of the transaction took place on 30 April 2018.
Orion's key research projects include three ongoing Phase III trials, among others.
Monthly updated list of Orion's major shareholders by votes.
Information about the price development of Orion's A and B shares. Also available a list of analysts covering Orion and the latest consensus estimate.
The latest Corporate Governance Statement of Orion Corporation is available at the archive of Corporate Governance Statements.
Orion Corporation has been included in the globally recognised FTSE4Good Index.
